
Shaily Engineering Plastics Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Healthcare segment expects strong volume growth, particularly from Q2 FY25 onwards, following resolution of Q1 technical issues.
- Anticipated revenue growth in Healthcare projected at 20%+ for FY25; consolidated growth driven by Healthcare expansion.
- New contracts and projects in Healthcare (e.g., Lanreotide, Semaglutide) expected to contribute revenues in coming quarters.
- Own IP insulin pen injector order for 10 million units per year indicates scaling opportunity; additional large insulin orders likely in next 1-2 years.
- UK business projected to grow 35-45%, with continued development projects fueling revenue.
- Consumer and Industrial segments expected to grow, with new projects in home furnishing and automotive components ramping up by Q2-Q3 FY25.
- Capacity expansions planned over next 18-24 months to meet growing demand, including doubling pen platform capacities.
- Overall focus on scaling business significantly over next 5 years with increased own IP product contribution.
See what Shaily Engineering Plastics management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Shaily Engineering Plastics management said on order book — free account, 30 seconds.
Capex plans
Yes- The company plans to expand some healthcare capacities over the next 18 to 24 months, including doubling up on some pen platforms to meet growing demand.
- No significant additional investment is needed to switch capacities from existing non-healthcare segments to other areas like automotive; only marginal investment in testing equipment or robotic handling may be required.
- The existing drug device capacity is 40 million devices, and the company is targeting to utilize and expand this capacity within the next 18 to 24 months.
- Shaily UK’s profitability is expected to grow alongside Indian manufacturing profitability, contributing to healthier consolidated numbers as scale increases.
- The company is at a very nascent stage in evaluating new opportunities in consumer electronics and will provide updates in due course.
Track Shaily Engineering Plastics — get its next earnings analysis in your feed
How does Shaily Engineering Plastics rank vs peers in Consumer Durables?
Pro featureHow does Shaily Engineering Plastics rank in Consumer Durables?
Compare Shaily Engineering Plastics against every Consumer Durables company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Shaily Engineering Plastics's management said in earlier quarters
Others in Consumer Durables this season
- Arham Tech (Q2 FY27)
Revenue from Operations for H1FY27: ₹85.48 Crores, an 87.34% year-on-year increase from ₹45.63 Crores in H1FY26 (Page 30, 29). Key investor presentation takeawa
- Khazanchi Jewell (Q2 FY27)
Q2 FY27 revenue from operations: ₹605.58 Crore, up 10.4% YoY (Q2 FY26: ₹548.60 Crore) [Page 7] . Key investor presentation takeaways from Khazanchi Jewellers Lt
- Uday Jewellery (Q2 FY27)
Q2 FY27 Total Income: ₹210.46 crore, up 30% year-on-year (YoY) . Key results statement takeaways from Uday Jewellery Industries Ltd's Q2 FY27 results statement
- Rajesh Exports (Q2 FY27)
Revenue from operations (net sales) for the quarter ended 30/09/2026: ₹2,895.85 million. Key results statement takeaways from Rajesh Exports Ltd's Q2 FY27 resul